u/Avish_Golakiya · 45d ago31 prior · 63% at 3mo
“Watching, favourite of three ESMO catalysts”
10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.
Bamzireotide navoxetan, an alpha emitter for neuroendocrine tumours, has dosed 76 patients in Phase 1/2a with updated data at ESMO Oct 23. $237M cash against $357M cap provides 33 months runway and full Phase 3 funding, making this author's favourite of three ESMO catalysts despite 24% short interest with slow 18-day cover.
At post $3.12Now $2.27-27.4% since posted2m ago
1d—
3d-11.2%
1w-6.4%
1m-21.2%
3m—
6m—
1y—